N-acetylcysteine Anxiety Meta-analysis: What the Evidence Says

Quick Answer

N-acetylcysteine Anxiety Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Detailed information on the composition, sources, functions and other relevant details can be found in Supporting Information : Appendix S1, including figure S1, which summarises the effect of nutraceutical supplements on key biological processes in mitochondria. [Tortajada Juan (2026); evidence level 1]
• In patients with early psychosis, Gaughran et al.found no significant differences between the vitamin D3 and placebo groups in mental health or metabolic outcomes. [Tortajada Juan (2026); evidence level 1]
• Individuals with PTSD exhibit sustained hyperactivation of the amygdala and disturbances of the prefrontal-limbic inhibitory network, associated with elevated neuroinflammatory signaling. [Ahmed Mohamed Awad E. (2026); evidence level 1]
• Beyond traditional models, recent evidence highlights that severe stress exposure, such as war-related trauma, can trigger profound depressive reactions and post-traumatic symptoms through a cascade of inflammatory activation, mitochondrial dysfunction, and redox imbalance. [Ahmed Mohamed Awad E. (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For n-acetylcysteine anxiety meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Tortajada Juan (2026). Clinical outcomes of mitochondrial‐enhancing nutraceutical supplementation in psychiatric disorders: A systematic review. DOI: 10.1002/gps3.70023. PMCID: PMC13239229. PMID: 42253799. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13239229/
• Ahmed Mohamed Awad E. (2026). N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials. DOI: 10.1186/s12888-026-08124-8. PMCID: PMC13162469. PMID: 42115982. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13162469/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.